Morgan Stanley lifts Sanofi [SNY] price estimate. Who else is bullish?

Sanofi [NASDAQ: SNY] slipped around -0.1 points on Tuesday, while shares priced at $48.53 at the close of the session, down -0.21%. The company report on January 18, 2023 that Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship program for people from numerous communities underrepresented in healthcare professions.

The program will help pay tuition and other expenses at institutions of higher education for students who are part of their nation’s ethnic minority groups, women, people with disabilities and members of the LGBTQ+ community who wish to pursue careers as doctors, nurses, scientists, researchers and other healthcare-related professions.

Sanofi stock is now 0.21% up from its year-to-date (YTD) trading value. SNY Stock saw the intraday high of $48.60 and lowest of $48.24 per share. The company’s 52-week high price is 57.79, which means current price is +2.43% above from all time high which was touched on 01/17/23.

Compared to the average trading volume of 2.59M shares, SNY reached a trading volume of 3648465 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Sanofi [SNY]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNY shares is $64.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNY stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Sanofi shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 13, 2022. The new note on the price target was released on August 12, 2022, representing the official price target for Sanofi stock.

The Average True Range (ATR) for Sanofi is set at 0.77, with the Price to Sales ratio for SNY stock in the period of the last 12 months amounting to 2.56. The Price to Book ratio for the last quarter was 1.71, with the Price to Cash per share for the same quarter was set at 2.95.

How has SNY stock performed recently?

Sanofi [SNY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.61. With this latest performance, SNY shares gained by 0.54% in over the last four-week period, additionally sinking by -3.54% over the last 6 months – not to mention a drop of -4.78% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNY stock in for the last two-week period is set at 52.86, with the RSI for the last a single of trading hit 47.48, and the three-weeks RSI is set at 55.58 for Sanofi [SNY]. The present Moving Average for the last 50 days of trading for this stock 46.98, while it was recorded at 48.97 for the last single week of trading, and 47.15 for the last 200 days.

Sanofi [SNY]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sanofi [SNY] shares currently have an operating margin of +22.95 and a Gross Margin at +63.07. Sanofi’s Net Margin is presently recorded at +16.48.

Return on Total Capital for SNY is now 9.72, given the latest momentum, and Return on Invested Capital for the company is 7.26. Return on Equity for this stock inclined to 9.45, with Return on Assets sitting at 5.30. When it comes to the capital structure of this company, Sanofi [SNY] has a Total Debt to Total Equity ratio set at 32.63. Additionally, SNY Total Debt to Total Capital is recorded at 24.61, with Total Debt to Total Assets ending up at 18.64. Long-Term Debt to Equity for the company is recorded at 27.61, with the Long-Term Debt to Total Capital now at 20.82.

Reflecting on the efficiency of the workforce at the company, Sanofi [SNY] managed to generate an average of $65,202 per employee. Receivables Turnover for the company is 3.83 with a Total Asset Turnover recorded at a value of 0.32.Sanofi’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.30.

Earnings analysis for Sanofi [SNY]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sanofi go to 12.30%.

Insider trade positions for Sanofi [SNY]

There are presently around $12,547 million, or 10.30% of SNY stock, in the hands of institutional investors. The top three institutional holders of SNY stocks are: DODGE & COX with ownership of 75,650,666, which is approximately -1.749% of the company’s market cap and around 16.40% of the total institutional ownership; FMR LLC, holding 18,203,971 shares of the stock with an approximate value of $883.44 million in SNY stocks shares; and BOSTON PARTNERS, currently with $860.11 million in SNY stock with ownership of nearly 48.926% of the company’s market capitalization.

Positions in Sanofi stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 270 institutional holders increased their position in Sanofi [NASDAQ:SNY] by around 28,882,839 shares. Additionally, 313 investors decreased positions by around 30,846,736 shares, while 126 investors held positions by with 198,811,223 shares. The mentioned changes placed institutional holdings at 258,540,798 shares, according to the latest SEC report filing. SNY stock had 77 new institutional investments in for a total of 5,769,775 shares, while 113 institutional investors sold positions of 4,888,571 shares during the same period.


Please enter your comment!
Please enter your name here